Why Pharmacovigilance (Phase IV Trials) will be increasingly seen: What do they tell us and why are they important?

Speaker

Instructor: Charles H Pierce
Product ID: 701635

Location
  • Duration: 75 Min
This Phase IV Trials training will help you in understanding FDA’s mandate on Phase IV trial and best practices for successful studies that meet the complex requirements.
RECORDED TRAINING
Last Recorded Date: Nov-2011

 

$50.00 $249.00 (79%)SAVE: $199.00
1 Person Unlimited viewing for 6 month info Recorded Link and Ref. material will be available in My CO Section
(For multiple locations contact Customer Care)

$149.00 $450.00 (66%)SAVE: $301.00
1 USB is for usage in one location only. info CD/USB and Ref. material will be shipped within 15 business days
(For multiple locations contact Customer Care)

 

 

Customer Care

Fax: +1-650-362-2367

Email: [email protected]

Read Frequently Asked Questions

Why Should You Attend:

FDA-mandated post-market studies are coming. Phase IV studies are likely to be complex in design and large in scale (possibly 500,000 patients per arm), with exacting endpoints, and obligatory. The FDA appears to be abandoning a long-standing policy of negotiating post-market commitments with sponsors - and will now set mandatory objectives and timelines. There is no one-size-fits-all guidance to help a particular drug or drug class prepare for the studies. There are, however Guidance documents for “Risk Minimization Action Plans” and “Good Pharmacovigilance Practices and “Pharmacoepidemiologic Assessment” and there is also the ICH E2E Guidance of Pharmacovigilance Planning. The likelihood of Data Monitoring Committees being required is also expected to increase.

Learning Objectives:

  • What is the rationale for such large studies.
  • What is Pharmacovigilance and what questions are answered.
  • The design and scope, of the types of Phase IV studies.
  • What will be the role of DMCs in post-market studies.
  • Operational strategies for successful studies that meet the requirements.
  • Methodsworking in the post-approval arena even when guidance is unclear.
  • Areas Covered in the Seminar:

    • The Nature of the I/E criteria in Phase IV studies.
    • How does the Safety Monitoring Plan differ in Phase IV?
    • What constitutes a “rare” adverse event?
    • What are the types of Phase IV studies?
    • Why large studies are needed to uncover rare Serious adverse events?
    • What is the value of a DMC in large studies?
    • What endpoints is the FDA looking for once they have approved a drug/device?

    Who Will Benefit:

    This Webinar will provide invaluable assistance to investigators and their staff in the regulatory / legal responsibilities and also the ethical considerations in pharmaceutical product (Drug or device) research involving human subjects. Those benefiting the most would be:
    • Holders of the IND for new products
    • Principal Investigators / Sub-investigators
    • Clinical Research Scientists (PKs, Biostatisticians)
    • Safety Nurses
    • Clinical Research Associates (CRAs) and Coordinators (CRCs)
    • Recruiting staff
    • QA / QC auditors and staff
    • Clinical Research Data managers

    Instructor Profile:
    Charles H. Pierce, MD, PhD, FCP, CPI is a consultant in the Clinical Research / Drug-Device Development arena specializing in bringing the message (via webinars, lectures and seminars) of Risk Management through knowledge of GCP Regulations and Investigator Responsibility to the entire investigative team to help them understand the regulations as well as the ethics of research involving human subjects. Dr. Pierce serves as an advisor to several clinical research organizations. He has been in the Clinical Research Industry for 20+ years, has been involved in developing Phase I & IIa Clinical Pharmacology Units, Investigator and staff GCP training, and medical monitoring in both drug and device studies.

    Follow us :

     

     

    Refund Policy

    Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
    Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).

     

     

    +1-888-717-2436

    6201 America Center Drive Suite 240, San Jose, CA 95002, USA

    Follow Us

    facebook twitter linkedin youtube

     

    Copyright © 2021 ComplianceOnline.com MetricStream
    Our Policies: Terms of use | Privacy

    PAYMENT METHOD: 100% Secure Transaction

    payment method